Corcept Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Corcept Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase shares under its 2024 Incentive Award Plan.
NASDAQ
Corcept Therapeutics will hold its annual stockholder meeting on June 10, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.
NASDAQ
Corcept Therapeutics issues a supplement to its proxy statement to correct the number of outstanding shares of common stock as of the record date for the upcoming annual meeting.
NASDAQ
DEF 14A: Corcept Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Corcept Therapeutics will hold its annual stockholders meeting on May 17, 2024, to vote on director elections, auditor ratification, executive compensation, and a new incentive award plan.